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Drug abuse is a serious problem worldwide. Recently, hallucinogens have been reported 
as a potential therapy for substance abuse. However, the use of hallucinogens as a drug abuse 
treatment itself has potential risks. The true mechanisms of hallucinogens are not clear. Thus it is 
necessary to investigate the mechanism of hallucinogens to make sure they are safe to develop as 
medicine. So far, no scientific database is available for the mechanism research of hallucinogens.  
We constructed a hallucinogen-specific chemogenomics database by collecting 
chemicals, protein targets and pathways closely related to hallucinogens. This information, 
together with our established computational chemogenomics tools, such as TargetHunter and 
HTDocking, provided a one-step solution for the mechanism study of hallucinogens.   
We chose salvinorin A as an example to demonstrate the usability of our platform. 
Salvinorin A is a potent hallucinogen extracted from the plant Salvia divinorum. It was the first 
reported non-nitrogenous kappa opioid receptor agonist. Recently, researchers found that oral 
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administration of salvinorin A can affect drug choice in a monkey model, which suggested a 
potential use of salvinorin A as an abuse-deterrent formulation. However, some complex effects 
of salvinorin A were reported, including depersonalization or laughing hysterically. Our aim is to 
identify the potential targets of salvinorin A to further explore the mechanisms of its complex 
effects. 
With the help of HTDocking program, we predicted four novel targets for salvinorin A, 
including muscarinic acetylcholine receptor 2, cannabinoid receptor 1, cannabinoid receptor 2 
and dopamine receptor 2. We looked into the interactions between salvinorin A and the predicted 
targets, and compared their binding modes with the known ligands of these proteins. The similar 
binding modes, interactions and high docking scores indicate that salvinorin A may interact with 
these four predicted targets. In the future, we will design experiments or find collaborators to 
validate our predictions. At the same time, we will continuously enrich our hallucinogen-specific 
chemogenomics database by adding newest data and building more 3D homology models. 
 
Key words: hallucinogen, salvinorin A, drug abuse, chemogenomics database, cloud 
computation, target identification, systems pharmacology, homology modeling, natural product, 
drug discovery. 
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1.0 INTRODUCTION 
 
1.1 DRUG ABUSE 
 
Drug abuse is a serious problem, killing about 200,000 people worldwide each year 
according to a new United Nations (UN) report. In 2009, alcohol, tobacco and illicit drugs 
together contributed to 12.6% of all deaths worldwide. Besides the calculation of deaths, the 
summary of disability-adjusted life-years (DALY) among the population can be considered as a 
measurement of the gap between the current health status and an ideal health situation. Table 1 
shows the deaths and DALY caused by the illicit drugs, alcohol and tobacco in 2009. The 
percentage of DALY for substance abuse is 9.0, which means about one tenth of a person’s 
healthy life time was lost because of drug abuse (1). Drug abuse threatens health, family, and 
social life significantly (2). According to a US government report, many people are struggling to 
overcome an addiction to drugs. The percentage of population who have ever used illicit drugs 
was rising continuously and arrived at 9.4 in 2013. According to Figure 1, using illicit drugs rose 
from 2002 to 2013 and seems likely to increase in the future, which means more people will be 
influenced (3). At this point, the analysis of existed treatments and the exploration of new 
therapy for drug abuse are necessary and urgent. 
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Table 1. The deaths and DALY caused by the illicit drugs, alcohol and tobacco in 2009 
(Modified from World Drug Report 2012) 
 
  Illicit drugs Alcohol Tobacco Total 
Deaths (millions) 0.25 2.3 5.1 7.6 
Deaths (percentage) 0.4 3.6 8.7 12.6 
DALY (millions) 13.2 69.4 56.9 139.5 
DALY (percentage) 0.9 4.4 3.7 9.0 
 
 
 
Figure 1. Percentage of the population using illicit drugs. The trend of people who have ever 
used illicit drugs was summarized from 2002 to 2013. It was continuously rising and arrived at 
9.4% in 2013.  (Modified from drugabuse.gov) 
 
We collected and analyzed the existing treatments for drug abuse. This data was 
downloaded from the drug abuse (DA) chemogenomics knowledgebase (DA-KB) 
(http://www.cbligand.org/CDAR) (4). Sixteen drugs were approved either by FDA or EU for 
drug abuse treatments like opioid-related disorders, drug overdose, alcoholism and withdrawal 
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delirium. The approved drugs include Nalorphine, Nikethamide, Lofexidine, Fosenazide, 
Naltrexone and so on. Nine drugs are withdrawn or discontinued from the market. Many of them 
have serious side effects like tachycardia, ventricular rhythm disorders, severe depression and so 
on. Compared to the number of approved drugs, more drugs are in clinical trials, especially on 
the phase II clinical trial. However, less drugs are investigated in other clinical trials (Figure 2).  
 
 
Figure 2. Drugs in different clinical trials that used for drug abuse treatments. Sixteen 
drugs were approved either by FDA or EU including Nalorphine, Nikethamide, Lofexidine, 
Fosenazide, Naltrexone and so on. Nine drugs are withdrawn or discontinued from the market for 
serious side effects like tachycardia, ventricular rhythm disorders, severe depression and so on. 
Many drugs are under clinical trials, especially on the phase II clinical trial. 
 
 
We looked deep into different treatments and their therapeutic targets for drug abuse 
treatments with multiple targets involved. We summarized the treatments of drug abuse and 
divided them into different groups based on the specific therapeutic targets of each drug. As 
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receptors (OPR), dopamine receptors (DRD), N-methyl-D-aspartate receptors (NMDA) as well 
as sodium-dependent dopamine transporters (SC6A3).  
 
 
 
Figure 3. Treatments of drug abuse in different clinical trials were divided based on 
specific therapeutic targets. Mu opioid receptor (OPRM), Dopamine receptor 2 (DRD2), 
Kappa opioid receptor (OPRK) were the top three commonly considered therapeutic targets for 
drug abuse treatments. N-methyl-D-aspartate receptors (NMDA), sodium-dependent dopamine 
transporter (SC6A3), sodium-dependent serotonin transporter (SC6A4), other subtypes of DRD, 
5HTR, OPR and cannabinoid receptors (CNR) were also considered to be important targets for 
treatments of drug abuse. 
  
Developing a good drug for addiction treatment is still a big challenge.  Although some 
famous hypotheses tried to explain the mechanisms of addiction, the underlying mechanisms are 
still complex and unclear. The most commonly accepted reason to explain why people are 
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continuously trying to seek drugs is the reward effect (5). The sense of euphoria promotes 
repeated drug use, leading to vulnerable individuals, unable to stop taking drugs over and over 
again. Common addiction circuitry is in the limbic system of brain. The well-known pathway is 
the VTA-NAc pathway. Drugs directly or indirectly activate the dopaminergic transmission in 
the NAc. Some drugs can directly stimulate dopaminergic pathway, causing an increase of 
dopaminergic transmission. Some directly act on opiates receptors on NAc. Some indirectly act 
on opiates receptors, inhibit GABAergic interneurons in VTA, which disinhibit dopaminergic 
transmission (Figure 4) (6, 7). The abuse effect of some drugs was reduced in the opioid and 
cannabinoid receptors knockout mice, which indicate that these drugs may also activate 
endogenous opioid and cannabinoid systems (8-10). 
 
                               
 
Figure 4. Simple diagram of VAT-NAc pathway. Drugs directly or indirectly activate 
dopaminergic transmission in the NAc. Some can directly stimulate the dopaminergic pathway, 
causing an increase of dopaminergic transmission. Some directly act on opiates receptors on 
NAc. Some indirectly act on opiates receptors, inhibiting GABAergic interneurons in VTA, 
which disinhibit dopaminergic transmission. (Modified from Nestler EJ. Nature neuroscience. 
2005;8(11):1445-9.) 
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Another point of view is that the anti-reward effect can dramatically impact the addiction 
progress (11). Different from trying to maintain the happy feeling from taking drugs, the anti-
reward effect emphasizes the dysphoria without drugs that force people to use drugs again. 
Dysregulation of the brain’s reward system and anti-reward system cause abnormal emotion that 
lead to the pathology state (11-13).                      
Drug abuse is a complex and serious problem that needed to be paid attention to 
worldwide. Multiple targets contributed to the drug abuse. The exact mechanism of drug abuse is 
still unclear. The existed therapy of drug abuse faces the challenges including not curable, 
serious withdrawn symptoms and so on. It is necessary and urgent to study drug abuse and find 
potential therapy.  
                    
 
1.2 HALLUCINOGENS 
 
Hallucinogens are powerful psychoactive substances that can modify the users’ mood, 
perception, consciousness, cognition and behavior. This class of compounds is considered to be 
safe physiologically and less possible to form addiction (14).  
 
1.2.1 Therapeutic value and side effects of hallucinogens 
 
Although hallucinogens are in the early stage of study for medical use, some applications 
already exist in the history. People have tried to use hallucinogens to treat substance abuse. For 
example, a study showed that lysergic acid diethylamide (LSD) was used to combat alcoholism 
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in 1950s and LSD, which was recently confirmed to significantly reduce alcohol consumption up 
to six-months (15). Recently, Dr. Matt Johnson’s group was engaged in a program to investigate 
the effect of psilocybin in long-term smokers and, so far, has gotten promising results (16). 
Ketamine was used to mitigate alcoholism and heroin addiction in 1985 and showed promising 
results (17). An observational study documenting the Ayahuasca, in which the major ingredient 
is dimethyltryptamine (DMT), was used to treat addiction in Canada. Participants showed a 
decreased use of alcohol, tobacco, and cocaine as well as significant improvements in 
hopefulness, empowerment, and mindfulness (18). 
 
Table 2. Therapeutic value of hallucinogens 
 
Hallucinogen  Therapeutic value  
Psilocybin  Terminal illness, Obsessive-compulsive disorder,  
 
Alcoholism, Smoking cessation 
LSD Obsessive-compulsive disorder, Alcoholism, Substance abuse,  
 
Terminal illness,Tools for cognitive neuroscience, 
Bufotenin Protection against burn, tourniquet and endotoxin shock 
Ketamine Antidepression, Pain, Mood disorder, Post-traumatic epilepsy, Anesthesia 
Salvinorin A Pain, Mood and personality disorders, Substance abuse,  
  Gastrointestinal disturbances 
 
 
Hallucinogens have other therapeutic potentials like in the treatment of mood, obsessive-
compulsive, gastrointestinal disorders and pain (Table 2). A preclinical study showed mice with 
pretreatment of bufotenin whom obtained great protection from burn, tourniquet and endotoxin 
shock (19, 20). Several case studies reported that hallucinogens like LSD, psilocybin or 
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mescaline improved symptoms of obsessive-compulsive disorder (21, 22). LSD and psilocybin 
can also dramatically reduce anxiety and stress among patients at the end of the cancer stage. 
Recently, Heffter’s research institute generated a Phase III clinical study to investigate the effects 
psilocybin in end-stage cancer patients (14, 16, 23). Ketamine is a popular club drug; however, 
this cannot detract from its great therapeutic value. Many studies pointed out its anti-depressive 
effect (24). It can also act as an analgesic for its block of N-methyl-D-aspartate receptors (25). 
New applications of ketamine emerg nowadays, such as the less established treatment for post-
traumatic epilepsy, anesthesia in the emergency department and operating theater setting (25, 
26).  
 
Table 3. Drugs for pathological laughing   
 
Class Drug 
Serotonin Reuptake Inhibitors (SSRIs) Fluoxetine 
 
Paroxetine 
 
Citalopram 
 
Escitalopram 
 
Sertraline 
Tricyclic Antidepressant (TCAs） Nortriptyline 
 
Amitriptyline 
 
Imipramine 
Other Antidepressants Reboxetine 
 
Venlafaxine 
 
Mirtazapine 
 
Lamotrigine 
Dopaminergic Drugs Levodopa 
 
Methylphenidate 
 
Dexamfetamine 
Uncompetitive NMDA Receptor Antagonists Dextromethorphan/quinidine 
  Amantadine 
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However, using hallucinogens to treat drug abuse has its potential risks, for example, 
researchers found some patients would be addicted to ketamine itself after treatments (27). 
Hallucinogens also have different hallucinogenic effects that bother people a lot. For example, 
salvinorin A has side effects like that people feel loss of control of the body or hysterical laugher 
(14). In this point of view, we believe that instead of the well-known kappa opioid receptor 
(OPRK), other off-targets contribute to those side effects. For targets collection purpose and the 
safe problem of further therapy, we collected the drugs clinically used for pathological laughing 
(Table 3).  
It was our objective to study the mechanism of hallucinogens and then to further make 
sure that they are safe to develop.  Mechanism study is also beneficial for figuring out the 
strategies to avoid side effects. The more we know about their mechanisms, the more we can 
know of their possible therapeutic values. So far, among all the targets involved, the serotonin 
receptors are the most important ones when it refers to the mechanism of hallucinogens. Almost 
all literature regarding the mechanism hallucinogen mentioned them. For example, serotonin 
receptor 2A (5HT2A) is the known target of many hallucinogens like LSD, ketamine, 2,5-
Dimethoxy-4-methylamphetamine (DOM) and psilocybin (14, 28, 29). However, hallucinogen is 
a broad class containing nearly fifty natural or synthetic compounds. Every kind of hallucinogen 
shared little overlap of mechanisms and most of them are unclear. To solve this problem, we 
applied computational technologies that offer the advantages of approach target identification 
more quickly and at a lower cost. Our goal is to build a hallucinogen specific chemogenomics 
knowledgebase and apply computational technologies for mechanisms research.  
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1.2.2 Salvinorin A 
 
Salvinorin A is the major ingredient of a Mexican plant, Salvia divinorum, that is a potent 
hallucinogen. It has potential therapeutic value for treating pain, mood and personality disorders, 
substance abuse and gastrointestinal disturbances (30). The Freeman’s group has designed an 
experiment using salvinorin A as a punisher of drug self-administration in monkeys. Compared 
to the administration of cocaine alone, the average percent of choice for the salvinorin A 
associated lever decreased dose dependently among all monkeys. It means that moneys were 
more likely to choose the lever with cocaine alone. This phenomenon was more obvious when 
cocaine was given associated with higher dose of salvinorin A as punisher. They arrived at the 
conclusion that salvinorin A can punish drug choice, which suggested a potential use in the 
development of abuse-deterrent formulations (31). 
 
 
Figure 5. Ligands of opioid receptors. Salvinorin A is a non-nitrogenous opioid receptor 
agonist that shared little structural similarity with other ligands of opioid receptors. 
 
The well-known target of salvinorin A is OPRK. The structure of salvinorin A is special. 
Compared to other opioid ligands, salvinorin A shared little structural similarity (Figure 5). It is 
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the first reported non-nitrogenous opioid receptor agonist. It is also the first known psychoactive 
diterpenoid. The structure information gave scientists a hint that nonalkaloids, such as salvinorin 
A, may be potential scaffolds for developing new drugs targeting on G-protein coupled receptors 
(GPCRs) (32).  
However, some reports pointed out that some users experienced a psychic 
depersonalization condition, which is a unique sensation of being disconnected from one’s body 
(32, 33). A double-blind, placebo-controlled study of vaporized/ inhaled Salvinorin A in eight 
hallucinogen-experienced adults showed that about half of the participants exhibited a positive 
affect (audible laughter) during peak drug effects and one described his feeling “I found myself 
hysterically, almost uncontrollably laughing.” (34)  
Based on the complex effects of salvinorin A listed above, we believe the concept of 
“multiple drugs, multiple targets interactions” can provide reasonable explanations. We 
hypothesized that in addition to the OPRK, other potential targets can also interact with 
salvinorin A. These interactions may contribute to the complex effects of salvinorin A. 
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2.0 METERIALS AND METHODS 
 
 
2.1 HALLUCINOGEN SPECIFIC KNOWLEDGEBASE 
 
To provide a comprehensive platform for various kinds of hallucinogens mechanism 
studies, we did data-mining of all the information. We collected hallucinogenic related 
compounds, proteins, signaling pathways, therapeutic targets and their associated bioassay data 
from literature and various public databases. Then, we compiled them into our in-house 
hallucinogen specific knowledgebase, where stored in a cloud computing server: 
www.cbligand.org/hallucinogen. This method generated by our lab is not a new one but 
gradually matured. Recently, our lab published two paper based on it, which are the drug abuse 
knowledgebase (DA-KB) (4) and the Alzheimer’s disease knowledgebase (AlzPlatform: 
http://www.cbligand.org/AD) (35). The features of our Hallucinogen specific knowledgebase are 
listed below: 
 
• Database infrastructure and web interface 
 
Hallucinogen specific knowledgebase is designed with a MySQL database 
(http://www.mysql.com) and an apache web server (http://www.apache.org) with OpenBabel 
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(36) at the back end as the search engine for chemical structures. The web interface is written in 
PHP language (http://www.php.net).  
 
• Data collection and content 
 
The hallucinogenic related targets data was collected from literatures and a variety of 
public databases including the ChEMBL database (37), DrugBank (38), ClinicalTrials.gov (39), 
BindingDB (40) and SuperTarget (41). The 3D crystal structures of targets were collected from 
Protein Data Bank (42, 43), while the related signaling pathways were gathered from the KEGG 
pathway database (44). After the data collection, all these chemical structures, bioactivity values, 
pathways, bioassays, and references were imported into our hallucinogen specific 
knowledgebase.  
 
• Chemo-informatics Tools 
 
To facilitate the in silico mechanism study of hallucinogen and drug design for their 
potential therapies for drug abuse, the hallucinogen specific knowledgebase cloud computing 
server also integrates diverse chemo-informatics tools based on state-of-the-art machine learning 
algorithms developed by our group or from public resources. The functions of our 
knowledgebase are designed into the following modules: 1) properties explorer 
(http://www.cbligand.org/hallucinogen/Property_Explorer.php); which can predict the chemical 
properties of interested molecules based on structures; 2) blood-brain barrier (BBB) predictor 
(http://www.cbligand.org/BBB), which can analyze the drug-likeness of the interested small 
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molecules; 3) PAINS predictor (http://www.cbligand.org/PAINS); 4) toxicity predictor 
(http://www.cbligand.org/Tox), which allows exclusion of molecules with potential safety issue 
in the early phase of drug discovery. In this thesis, we mainly applied two of our developed 
systems pharmacological analysis tools, HTDocking and TargetHunter, which core functions in 
our hallucinogen specific knowledgebase.  
 
 
2.2 SYSTEMS PHARMACOLOGICAL ANALYSIS TOOLS 
 
 
• HTDocking 
 
Our lab established an online high-throughput docking program, HT-Docking, 
(http://www.cbligand.org/hallucinogen/docking_search.php) that is a web-interface computing 
tool that can produce docking procedures automatically (Figure 6). The docking study provided 
us the information of interactions between compounds and targets. In the current version of 
hallucinogen specific knowledgebase, crystal structures of hallucinogenic related protein targets 
have been collected from Protein Data Bank (http://www.rcsb.org/pdb) (43) and for the targets 
that are lacking crystal structures, homology models are also established by Modeller (45). With 
all of this information we collected, we built a hallucinogen specific knowledgebase. All of the 
original ligands are removed from the crystal structures to avoid unnecessary interaction with our 
interested compounds. Water molecules and ions are removed from the crystal structures if 
necessary. Pockets are defined according to the co-crystal structure ligands, or automatically 
predicted by the MOLCAD module implemented in SYBYL-X 1.3 based on our publications 
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(46-48). After submitting our interested compounds, docking scores are used to assess and rank 
potential targets. Docking scores are calculated based on the interactions between molecular 
compounds and targets like hydrogen bonds, van der Waals interactions and hydrophobic 
interactions. The scores represent the predicted values of -log10(Kd) of a compound with its 
predicted targets (49). So we analyzed the results and chose those with docking scores above six, 
which means the predicted Kd value of this compound with its target should be within the 
micromole range or even better. We used SYBYL-X 1.3 to further analyze the detailed 
interactions (50). 
 
     
 
Figure 6. Schematic diagram of HTDocking. Submit structures to the HTDocking website, 
then the program will automatically define the pockets and do an online docking study. The 
docking results can be retrieved anytime with the specific website. 
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• TargetHunter 
 
TargetHunter is a ligand-based tool (http://www.cbligand.org/TargetHunter). It was 
designed based on the principle that structurally similar compounds have great possibility 
sharing similar targets and biological profiles (51-53). After uploading the interested compounds, 
TargetHunter can provide not only the targets information, but also structures of the similar 
compounds and their related bioassays.  It can also provide the address information of related 
bioassays nearby (Figure 7). Detailed descriptions can be found in our published paper (54). 
 
            
Figure 7. Schematic diagram of TargetHunter.  Submit structures to the TargetHunter website 
and choose the value of similarity, then the program will automatically search similar 
compounds above that similarity based on the molecular fingerprint. The results will be 
presented from high to low similarities. TargetHunter will provide information including the 
structures of similar compounds as well as their targets, bioassays, references and map of the 
bioassays. 
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2.3 HOMOLOGY MODELING 
 
For those important targets without crystal structures, we built 3D homology models. In 
our hallucinogen knowledgebase, 21 GPCR homology models were added. Figure 8 shows a 
simple schematic diagram of the procedure of how to build 3D homology models. First, the 
whole sequence of targets were obtained from the UniProtKB / Swiss-Prot 
(http://www.uniprot.org/uniprot/) (55). The templates were searched from Protein Data Bank 
according to sequence identities. The 3D homology models were much closer to the natural 
structures with higher sequence identities. Second, the sequences and templates were aligned 
using the Modeller 9.12 software (56). In the meantime, we adjusted the alignments according to 
the literature. Finally, we built homology models. More detailed processes can be found in our 
published protocol (48). These models can be validated through screening against the known 
active and inactive compounds of the targets. In our case, this work has been already done 
previously in our lab (GPCRs database), so we compared our models with those established 
ones. 
 18 
 
Figure 8. Procedure of 3D homology modeling. First, we searched the whole sequences of 
proteins from Uniprot. Then we did a template search from the protein data bank according to 
the sequences identities. Second, we did alignments of the sequences and the templates using the 
Modeller 9.12 software. Alignments were adjusted according to the literature. Finally, we built 
homology models. The models were validated by screening known compounds for the targets.  
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3.0 RESULTS 
 
3.1 GPCR HOMOLOGY MODELS 
 
In our hallucinogen-specific knowledgebase, twenty-one homology models of G-couple 
protein receptors were established including 5HTR, ACM, OPR, DRD, cannabinoid receptors 
(CNR) and adrenergic receptors (ADAR). All of them were compared with our in-house data (86 
GPCRs Database) to make sure the established models were accurate. For example, Figure 9 
shows the alignments between each of five subtypes of ACM with our GPCRs database. The 
green ones were the models we built in our hallucinogen-specific knowledgebase, where the blue 
ones were from our 86 GPCRs database. Conserved and important residues within pockets were 
pointed out for comparison. The positions of the two comparable residues were the same. Most 
angles of the two comparable residues were almost the same.  
 Most of GPCRs consisted of two major pockets, the traditional binding site, orthosteric 
binding pocket and recently discovered allosteric binding site (57). In our situation, we defined 
the conserved orthosteric binding site of GPCRs for further study.   
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Figure 9. 3D homology models of muscarinic acetylcholine receptor (ACM).  The green ones 
represent the models we built for our hallucinogen-specific knowledgebase. The blue ones 
represent the models from our 86 GPCRs database. (A) the comparison between the two models 
of ACM1 and the important residues. Similarly, (B) - (E) the comparisons between the two 
models of ACM2 to ACM5 and their important residues.  
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3.2 HALLUCINOGEN RELATED TARGETS AND PATHWAYS 
 
Hallucinogen related chemicals, targets and pathways were collected from literature and 
databases including PubMed   (www.PubMed.org), PubChem (www.Pubchem.org ), DrugBank 
(www.drugbank.ca), ChEMBL  (www.ebi.ac.uk/chembl/), KEGG (www.genome.jp/kegg/), PDB 
(www.pdb.org) and so on. 46 hallucinogenic compounds referring 102 targets and 158 related 
pathways were collected. The biggest class of targets were the membrane receptors, representing 
over one third of hallucinogen targets. These membrane receptors included 5HTR, ACM, OPR, 
DRD, CNR and so on. The second biggest class of targets was enzymes. 30% of hallucinogen 
related targets were enzymes include amine oxidases (AOF), ras-related C3 botulinum toxin 
substrates (RAC), surase-isomaltase (SUIS), CYP enzymes and so on. Ion channels occupied a 
great proportion too. Hallucinogen related targets also included other classes, like transporters, 
epigenetic regulators, transcription factors and some unclassified proteins (Figure 10).  
 
 
Figure 10. Summary of targets for hallucinogens. 102 hallucinogens related targets were 
summarized according to 46 hallucinogenic compounds.  
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Among those hallucinogen related pathways, 5HT2A played an essential role in most of 
hallucinogen mediated pathways. By now, the two most important and proved pathways were 
5HT2A mediated PLC and PLA2 pathways. Figure 11 shows the simple schematic diagram of 
the 5HT2A mediated PLC pathway, where 5HT2A coupled with Gαq activate PI-specific 
phospholipase C (PLC). PLC hydrolyzed phosphatidylinositol (PIP2), then generated nositol-
1,4,5-triphosphate (IP3) and diacylglycerol (DAG). IP3 acted on the IP3 receptor located on the 
smooth endoplasmic reticulum triggers the release of calcium, where DAG acitivated protein 
kinase C (PKC) (14, 58). 
 
 
Figure 11. Schematic diagram of the 5HT2A mediated PLC pathway. 5HT2A coupled with 
Gαq activated PI-specific phospholipase C (PLC). PLC hydrolyzed phosphatidylinositol (PIP2), 
generated nositol-1,4,5-triphosphate (IP3) and diacylglycerol (DAG). IP3 acted on the IP3 
receptor triggered the release of calcium, where DAG acitivated protein kinase C (PKC). 
(Modified from Weinstein H. Drug addiction: springer; 2008. p. 265-86.) 
 
Compared to PLC-mediated signaling, the PLA2 pathway was more complicated. Figure 
12 shows the simple schematic diagram of the 5HT2A mediated PLA2 pathway, where 5HT2A 
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coupled with Gαi/o stimulate phospholipase A2 (PLA2). PLA2 hydrolyzed AA-containing 
phospholipids and then generated arachidonic acid (AA) and lysophospholipid (14, 59). It was 
also proposed that the simulation of PLA2 is through a Gαi/o-Ras-Raf-MEK-ERK signaling 
cascade (60). 
 
 
 
Figure 12. Schematic diagram of the 5HT2A mediated PLA2 pathway. 5HT2A coupled with 
Gαi/o stimulated phospholipase A2 (PLA2). PLA2 hydrolyzed AA-containing phospholipids, 
generated arachidonic acid (AA) and lysophospholipid. (Modified from Kurrasch-Orbaugh DM, 
et al. Journal of pharmacology and experimental therapeutics. 2003;304(1):229-37.) 
 
 
 Recently, the 5HT2A mediated phospholipase D (PLD) pathway was proposed (61). PLD 
can hydrolyze the terminal diester bond of phosphatidyl choline and then generates phosphatidic 
acid and choline. It was also involved in a phospatidyl transfer reaction. However, this signaling 
still needs to be further proved (14). 
 
 24 
 
3.3 SYSTEMS PHARMACOLOGICAL ANALYSIS OF HALLUCINOGENS 
 
 
Systems pharmacology is the study of drugs, drug-target interactions and drug effects in a 
macroscopic view, combining large-scale biological experiments data with computational 
analysis (62). Systems pharmacology focuses on big data analysis, which tends to believe in 
“multiple drugs, multiple targets interactions”, unlike the traditional concept “one drug, one 
target interaction” (63). In this way, it has obvious advantages of rapid identification of the 
networks and connections among different drugs and targets. It is a very useful method for quick 
analysis of drug repurposing. It is also beneficial to analyzing the complex drug adverse effects 
(62-65). 
  As described in the method section, we put several hallucinogenic compounds into 
HTdocking program of Hallucinogen Knowledgebase (www.cbligand.org/hallucinogen/). In 
order to validate our database, we selected five representative hallucinogenic compounds that 
share little structural similarity to perform the docking results. Based on the docking scores, we 
drew a map that showed the relationship between compounds and their targets. As shown in 
Figure 13, five compounds were listed including ketamine, LSD, mescaline, DMT and salvinorin 
A. All of the targets listed in the map were with docking scores above six, indicated that the Kd 
values should be within micromole range or even better. For example, the docking score between 
salvinorin A and the kappa opioid receptor was 7.40. This was congruent with the fact that the 
kappa opioid receptor is a known target of salvinorin A (Ki value of 16nM at OPRK) (66, 67). 
Similarly, as Figure 13 illustrates, 5HT2A, 5HT6R and 5HT7R were the known targets of DMT. 
5HT2A was also the target of mescaline and LSD. 5HT1A was the target of Ketamine, 
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Mescaline, DMT and LSD. Our docking results matched the information we collected either 
from literature or databases, which meant this method is reliable. 
 
 
Figure 13. Systems pharmacological analysis of known hallucinogens.  
ABBREVIATIONS, 5HT=5-hydroxytryptamine receptor, ACM=Muscarinic acetylcholine 
receptor, ADA1A=Alpha-1A adrenergic receptor, AOFA=Amine oxidase [flavin-containing] A, 
AOFB=Amine oxidase [flavin-containing] B, CNR=Cannabinoid receptor, OPRK=Kappa opioid 
receptor, DRD2=Dopamine receptor 2, CP2B6=Cytochrome P450 2B6, CP2D6=Cytochrome 
P450 2D6, NCF2=Neutrophil cytosol factor 2, RAC1=Ras-related C3 botulinum toxin substrate 
1, SPRE=Sepiapterin reductase, SUIS=Sucrase-isomaltase 
 
 
 
 
Hallucinogens 
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Other experimentally identified targets 
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 However, this method has its own limitations. As we discussed before, all of these 
validations and predictions were structure-based investigations. Since several targets didn’t have 
crystal structures, we tried to build reliable homology models for the future study. So far, we 
have built homology models for GPCRs. Compared to other receptors, the structures of GPCRs 
are well studied and characterized. They are very important for drug developments, especially 
for CNS drugs. By now, about 40% of drugs currently on the market are targeting GPCRs (68). 
In our case, 5HTR were very classic targets of hallucinogens. The reliable structures were a 
footstone for the future study of hallucinogens in depth. But there were still large amounts of 
structures that need to be established, especially like ion channels and kinase for their complex 
structures and less characterized features. In our case, the known target of ketamine was 
glutamate receptor ionotropic, N-methyl-D-aspartate receptor 3A (NMDA 3A). Since lack of its 
crystal structures, NMDA 3A was not in our map. To enrich our knowledgebase, besides GPCRs, 
we will build more homology models for the further study.  
 
 
3.4 SYSTEMS PHARMACOLOGICAL ANALYSIS OF SALVINORIN A 
 
 
  After our hallucinogen knowledgebase validation, we mapped out the interactions 
between salvinorin A and its related targets. At the same time, we coupled HTdocking results 
with the results from TargetHunter (Figure 12). Because of the principle, structurally similar 
compounds had great possibility sharing similar targets and biological profiles (51-53). We 
further mapped out to see if salvinorin A and similar compounds may share the same predicted 
targets. In Figure 14, we chose three compounds from TargetHunter that are structurally similar 
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to salvinorin A, which all the similarities were above 0.70 and targeting the OPRK 
(CHEMBL196670, Ki = 28.7nM; CHEMBL371079, Ki = 3.2nM; CHEMBL363825, Ki = 
83.2nM) (69). The similar compounds tended to interact with CB2 instead of CB1. It might 
depend on whether they had the amino group or not. From our docking results, we found that 
ligands with the ester bond instead of the amino group tend to form both hydrogen bonds and 
charge-charge interactions with Ile150 in extracellular loop 2 region of CB1 (Figure 18). It may 
explain the possible selection of CB2 instead of CB1 of these two similar compounds 
(CHEMBL371079 and CHEMBL363825) with the amino group. This idea was supported by 
literature, from which we noticed that the extracellular loop 2 of CB1 is important for binding. 
The Bertalovitz’s group farther pointed out Ile150 was an important residue of CB1 (23, 70). 
After the systems pharmacological study, we continued looking in depth into each one and 
discussed the detailed interactions.  
                                                      
Figure 14. Systems pharmacological analysis of salvinorin A and its similar compounds. 
Three other similar compounds of salvinorin A were chosen from TargetHunter. Kappa opioid 
receptor is the known target for all of them. Four other targets including CB1, CB2, ACM2, 
DRD2 were predicted according to TargetHunter and HTDocking results. 
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First, the OPRK was the well-known target of salvinorin A. Salvinorin A had high 
affinity with both cloned OPRK (Ki = 16nM) and guinea-pig brain OPRK (Ki = 4.3nM) 
according to radioligand binding assays (66, 67). We used the co-crystal structure of OPRK 
(PDB entry: 4DJH, resolution 2.90 Å) to do a docking study for salvinorin A. The original 
ligand, JKTic, was a selective OPRK antagonist with a high affinity (Ki = 0.32nM) (71). Figure 
15A shows the original interaction within the co-crystal structure. JDTic fitted tightly within the 
pocket forming ionic, hydrogen bonds and hydrophobic interactions with helix II, III, V, VI and 
VII. Asp138 formed salt bridges with amino in both piperidine and isoquinoline moieties of 
JDTic. Tyr139 formed a hydrogen bond with the amide linkage of JDTic. According to the 
modeling study and residues’ mutations, Asp138 was a key residue (71, 72). A literature study 
showed that the Asp138 residue was conserved and important in all aminergic GPCRs (73). The 
residues listed in the Figure 15 included Thr111, Gln115, Val118, Trp124, Val134, Leu135, 
Asp138, Tyr139, Met142, Lys227, Val230, Trp287, Ile290, His291, Ile294, Tyr312, Ile316, 
Tyr320 were proven essential for ligands binding with OPRK (71).  
We docked salvinorin A into the crystal structure, OPRK (PDB entry: 4DJH, resolution 
2.90 Å). The pocket was defined according to the original ligand of the co-crystal, JDTic. The 
docking score was 7.40. Figure 15B shows the interactions between salvinorin A and OPRK. 
Compared to the original ligand, we found that salvinorin A was closer to helix II, III, VI and 
VII. Tyr312 and Gln115 formed strong hydrogen bonds with the ester bonds of salvinorin A. In 
the original co-crystal structure, Tyr312 was reported to be an important residue for selectivity of 
JDTic with the kappa opioid receptor (71). These may explain the high selectivity of salvinorin 
A with the OPRK. From our docking results, we found the moiety of the pocket that is closer to 
helix II, III, VI and VII are more important for ligands binding to OPRK. 
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Figure 15. Interactions between salvinorin A and kappa opioid receptor (OPRK).  The red 
dash lines represent the hydrogen bonds between the ligands and targets. The blue dash lines 
represent charge-charge interactions between the ligands and targets. (A) The co-crystal structure 
of OPRK (PDB entry: 4DJH, resolution 2.90 Å). The original ligand, JDTic, fitted tightly within 
the pocket forming ionic, hydrogen bond and hydrophobic interactions with helix II, III, V, VI 
and VII. The important residues were labeled. (B) The docking results between salvinorin A and 
OPRK. The salvinorin A interacted closer to the moiety of the pocket, helix II, III, VI and VII. 
 
According to the prescreening HTDocking study, we found four promising targets of 
salvinorin A (Figure 13). The most potential one was the ACM2, which had the docking score of 
8.32 (Figure 16). The molecular docking study was based on the co-crystal structure of ACM2 
(PDB entry: 3UON, resolution 3.00 Å) published by Haga’s group in 2012 (74, 75).  The original 
ligand was QNB, an antagonist of ACM2 (Kd = 0.2nM). Figure 16A shows the interactions 
between QNB and helix III, IV, V, VI and VII of ACM2. Asp103, Tyr104, Ser107, Trp155, 
Phe181, Trp400, Tyr403, Asn404 and Cys429 listed in Figure 16 were the important residues 
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within the binding pocket. The amine moiety of QNB formed a salt bridge with the side chain of 
Asp103 in TM3, which was proven to be important by modeling study, mutagenesis and 
covalent-labeling experiments (74, 75). Asn404 formed hydrogen bonds with both hydroxyl and 
carbonyl group of QNB. However, according to the residues’ mutation result, Asn404 was not 
important for the interactions between endogenous acetylcholine and the receptor (74, 75). 
Phe181 and the benzene ring formed a weak π-π interaction. Indeed, Phe181 was the unique 
residue for ACM2, in which this position for other ACM was leucine (74). These might explain 
the reason why QNB was not a highly selective ligand of ACM2.  
Salvinorin A was located in the same pocket as QNB at ACM2. The positions and poses 
of QNB and salvinorin A in ACM2 were highly similar. Some similar interactions of salvinorin 
A could be found. Asn404 formed a hydrogen bond with the ester bond of salvinorin A. Ser107 
formed a hydrogen bond with another part of the ester bond of salvinorin A. Trp400 and the 
ternary heterocyclic ring of salvinorin A formed hydrophobic contact. Similarly, Trp400 had 
hydrophobic contact with the nitrogen heterocyclic ring of QNB from the original co-crystal 
(74). According to the residues mutations study, mutation of Tyr104, Trp155, or Trp400 reduced 
both agonist and antagonist binding affinity over 10 fold. Based on these similar interactions, we 
could predict that ACM2 was a potential target of salvinorin A.    
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Figure 16. Interactions between salvinorin A and muscarinic acetylcholine receptor 2 
(ACM2). (A) The co-crystal structure of ACM2 (PDB entry: 3UON, resolution 3.00 Å). (B) The 
docking results between salvinorin A and ACM2. QNB, the original ligand of ACM2, and 
salvinorin A have similar position and pose within binding pocket of ACM2. (C) 2D version of 
the interactions between QNB and ACM2. (D) 2D version of the interactions between salvinorin 
A and ACM2. The important residues were listed. 
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Besides ACM2, our HTDocking results showed that CB1 and CB2 had highly possibility 
to interact with salvinorin A. Since there were no crystal structures of cannabinoid receptors, we 
built the homology models to do the docking studies. (The detail methods have been mentioned 
in Chapter 2.0). The binding pocket of CB2 mainly located in helix III, V, VI and VII (Purple 
region in Figure 17B). The important residues of CB2 were Phe87, Phe91, Phe94, Asp101, 
Phe106, Lys109, Ile110, Val113, Phe117, Glu181, Leu182, Phe183, Trp194, Phe197, Trp258, 
Val261, Met265, Lys278, Lys279, Phe281 and Ser285 (Highlighted with green in Figure 17B). 
This model was validated by virtual screening, molecular dynamics simulation, and residues’ 
mutations coupled with experiments radio-ligand binding results (46).  
 
 
 
Figure 17. Interactions between salvinorin A and cannabinoid receptor 2 (CB2). (A) The 
interactions between salvinorin A and CB2. (B) The 3D homology model of CB2. The pocket 
was emphasized in purple. The important residues within pocket were highlighted with green.  
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The docking result between salvinoin A and CB2 was 8.11. In extracellular loop 2 region, 
Leu182 formed a hydrogen bond with the ester bond moiety of salvinoin A. As literature 
reported, extracellular loop 2 region of CB2 was proved essential for ligand bindings (76, 77). 
Besides, the amine part of Lys109 in helix III formed a hydrogen bond with the oxygen of 
salvinorin A. Lys109 is a conserved residue in GPCRs. Phe281 had hydrophobic contact with the 
ternary heterocyclic ring of salvinorin A. In summary, salvinorin A preferred hydrophobic 
interactions within CB2 binding pocket with residues including Phe91, Phe94, Phe106, Ile110, 
Trp194, Phe197, Trp258 and Phe281.  
CB1 shared 48% of the whole sequence identity and 68% of the trans-membrane domains 
sequence identity with CB2 (46). We used the same method to construct the CB1 homology 
model. We used the MOLCAD module implemented in SYBYL-X1.3 to explore its potential 
binding pocket. Based on the model reported by literature, our pocket was reasonable (Figure 
18B) (46, 78). The binding site of CB1 mainly focused on helix III, V, VI and VII, which was 
similar to CB2. The important residues listed in Figure 18B included Ile150, Phe57, Phe60, 
His61, Lys75, Val79, Asp149, Leu216, Met220, Phe236, and Ser240 (78). 
We got a relatively high docking score of 9.62 when salvinorin A interacted with CB1. 
Amino part of His61 formed a hydrogen bond with the furan moiety of salvinoin A. The furan 
also had a π-π interaction with Phe57. Both the hydrogen bond and the π-π interaction 
contributed to the slightly extend of the furan moiety of salvinorin A to helix II. In the 
extracellular loop 2 region, Ile150 formed a hydrogen bond with salvinorin A. The insight 
interactions between salvinorin A and CB1, CB2 indicated that these two targets might also 
contribute to the pharmacological effects of salvinorin A. 
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Figure 18. Interactions between salvinorin A and cannabinoid receptor 1 (CB1). (A) The 
interactions between salvinorin A and CB1. The purple dash lines represent the π-π interactions 
between Phe57 and the furan moiety of the salvinorin A. (B) The 3D homology model of CB1. 
The pocket was emphasized in pink. The important residues within pocket were highlighted with 
yellow. 
 
DRD2 played a central role in pathophysiology of psychosis, movement disorders such as 
Parkinson’s disease or multiple system atrophy, and addiction (79-81). It was also reported 
associative with pathological laughing (82). This indicated that DRD2 might contribute to the 
hysterically laughing side effect of salvniorin A. We got the docking score of 7.76 for salvinoin 
A within the DRD2 homology model. The homology model of DRD2 was established according 
to the template of DRD3 (83, 84). Figure19 shows that Ser157 and Ser161 formed a strong 
hydrogen bond (with 2.8 Å) with the ester moiety of salvinorin A. Tyr240 formed a hydrogen 
bond with the oxygen. Salvinorin A fitted well within the binding pocket that formed by helix 
III, V, VI and VII. The important residues in the binding pocket were Asp78, Cys82, Ser157, 
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Ser161, Trp210, Phe213, His217, Thr236 and Tyr240 (83, 84). Based on these similarities, we 
suggested salvinorin A might bind to DRD2. 
 
  
 
Figure 19. Interactions between salvinorin A and dopamine receptor 2 (DRD2). (A) The 
interactions between salvinorin A and DRD2. (B) The 3D homology model of DRD2. The 
pocket was emphasized in pink. The important residues within pocket were highlighted with 
green.  
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4.0 DISCUSSION 
 
 
The hallucinogen specific knowledgebase constructed in this study is essential for the 
mechanism study and off-target identifications. Some other open source websites only provide a 
part of hallucinogen information. For example, some related websites, General Hallucinogen 
Information (www.pearltrees.com), CPSG (www.cpsg.org.uk/Drug-Database.aspx), Drugs 
Encyclopedia Bolg (drugsencyclopedia.net/) and Paid Clinical Trials 
(www.paidclinicaltrials.org), they all only provide some general information about hallucinogens, 
either including fancy articles or pictures for the purpose of popularization of science. And none 
of them is a scientific database that can be used for the research of hallucinogens. Our 
hallucinogen specific knowledgebase established in this study is the first comprehensive 
database for hallucinogenic drug research, which also includes several analysis tools 
(HTDocking, TargetHunter, BBB Predictor, properties explorer, the pains predictor, toxicity 
predictor). It could provide a quicker, less costly and relatively easier way for researchers to do 
systems pharmacological analysis, off-target identifications and mechanism studies.  
Benefited from our hallucinogen specific knowledgebase, we applied it to explore 
possible targets of a special hallucinogen – salvinorin A. We found that besides OPRK, CB1, 
CB2, ACM2 and DRD2 might also be involved in the pharmacological effects of salvinorin A. 
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Actually, there was already some literature that could support our predictions. Seeman’s group 
designed an in vitro experiment testing the binding affinity of salvinorin A at D2High receptor. 
D2High receptor is an agonist high-affinity state of DRD2. They found salvinorin A had EC50 
values of 89 nM at the D2High receptor and were blocked by 10 µM S-sulpiride, an antagonist of 
DRD2. They claimed that the D2High receptors may be more pathophysiologically important 
than the overall expression of dopamine 2 receptors (85). However, the overall effects of 
salvinorin A on DRD2 still need to be further tested. Since it was proven that DRD2 contributed 
a lot to the pathological laughing (82), we assumed that the interaction with DRD2 should be 
blamed for the serious side effect, hysterical laughter of salvinorin A. 
  As we discussed in the introduction section, the dopaminergic system and the 
cannabinoid system are very important for the mechanism of addiction. Based on our similarity 
search results and docking results, we predicted that targeting on CB1, CB2 or DRD2 could 
explain the potential therapeutic profile of salvinorin A to treat drug abuse. Some related 
literature supported our idea. The Capasso’s group reported the inhibitory effect of salvinorin A 
on ileitis-induced hypermotility. They believed that the cross-talk between the kappa opioid 
receptor and CB1 contributed to this effect. All their experiments were designed based on 
pathological conditions that in the inflamed gut (86). However, we believed that the effects of 
salvinorin A on the normal condition should also be considered. At this point, whether salvinorin 
A acts on CB1 or CB2 under health conditions should be tested in the future. Later, Fichna’s 
group got interesting results of the effects of salvinorin A on colonic. They found differences 
between in vivo and in vitro phenomena, where the effects of salvinorin A on colonic motility in 
vitro were inhibited by antagonists of OPRK, CB1 and CB2, but in vivo the effects were largely 
mediated by OPRK (87). The reasons for these different results still need to be discussed.  
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ACM2 is expressed both in the central nervous system (CNS) and the periphery system, 
especially in heart and smooth muscle tissues. They are involved in the smooth muscle 
contractility through both direct and indirect mechanisms (88). We assumed that the effects of 
salvinorin A on colonic motility is partly because of its interactions with ACM2. Besides, the 
Capasso’s group also found that salvinorin A depressed enteric cholinergic transmission in the 
guinea-pig ileum. They concluded that this effect was triggered through OPRK. However, we 
can’t exclude the possibility of the function of ACM. 
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5.0 CONCLUSIONS AND FUTURE SPECULATION  
 
 
In our study, we established a hallucinogen specific knowledgebase by collecting 
hallucinogenic related data and constructing 3D homology models. We used our knowledgebase 
to study the mechanism of hallucinogens, a class of compounds that have recently been 
considered of its emerging potential drug abuse therapy. One case, salvinorin A was discussed in 
this thesis. The results showed that besides OPRK, four new receptors were predicted for the 
complex effects of salvinorin A, including ACM2, CB1, CB2 and DRD2 (Table 4). In the future, 
we are going to validate our predictions by experiments. Once we validate the predicted targets 
and the effects they contributed, we would combine the chemistry experiment methods with our 
computational techniques to process the structur-activity relationship (SAR) study. And finally, 
if possible, we will be able to modify the structure of salvinorin A to reduce its side effects and 
to increase its drug-likeness properties.  
 
Table 4. Targets that needed to be validated for salvinorin A 
 
Targets  Docking Score Related reference 
Muscarinic acetylcholine receptor 2 8.32 
 Cannabinoid  receptor 1  9.62 (86) (87) 
Cannabinoid  receptor 2  8.11 (86) (87) 
Dopamine  receptor 2 7.76 (82) (85) 
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Figure 20. Schematic diagram of lead compounds exploring by computational approach. 
Structure-based and ligand-based virtual screening were used to extract lead compounds from 
compounds library. During structure-based virtual screening, the accurate crystal structures or 
3D homology models are needed, in which identifying the pockets was critical. For ligand-based 
exploration, several strategies could be used, such as pharmacophore studies, similarity search, 
R-group replacement and scaffold-hopping. 
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Furthermore, for those promising therapeutic targets, we could do further study for drug 
discovery. Figure 18 shows our basic computational strategies for drug discovery and 
development. (89) As shown in this schematic diagram, the two major methods for extracting 
lead compounds from larger compound libraries were structure-based and ligand-based virtual 
screening, in which they can work independently or complementarily. During structure-based 
virtual screening, the accurate crystal structures or 3D homology models are needed, in which 
identifying the pockets was critical. For ligand-based exploration, several strategies could be 
used, such as pharmacophore studies, similarity search, R-group replacement and scaffold-
hopping. In a word, ligand-based screening was much quicker, convenient and beneficial for 
structure modifications, while structure-based screening had big advantages of exploring novel 
ligands for the therapeutic targets. For our hallucinogen specific knowledgebase, we will keep 
updating hallucinogenic related information and establishing more 3D homology models if 
necessary. Meanwhile, we will start more promising case studies in this area. 
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APPENDIX ABBREVIATION 
 
DALY Disability-adjusted life-years  
5HT Serotonin receptors  
5HT2B Serotonin receptors 1B 
5HT1B Serotonin receptors 2B 
5HT2A Serotonin receptors 2A 
5HT6R Serotonin receptors 6 
5HT7R Serotonin receptors 7 
AA Arachidonic acid  
ACM Muscarinic acetylcholine receptors  
ACM2 Muscarinic acetylcholine receptor 2  
ADA1A Alpha-1A adrenergic receptor 
ADAR Adrenergic receptors  
AOF Amine oxidases  
AOFA Amine oxidase [flavin-containing] A 
AOFB Amine oxidase [flavin-containing] B 
BBB Blood-brain barrier  
CB1 Cannabinoid receptor 1 
CB2 Cannabinoid receptor 2 
CNR Cannabinoid receptors 
CNS Central nervous system  
CP2B6 Cytochrome P450 2B6 
CP2D6 Cytochrome P450 2D6 
DA Drug abuse 
DA-KB Drug abuse chemogenomics knowledgebase  
DAG Diacylglycerol 
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DMT Dimethyltryptamine 
DOM 2,5-Dimethoxy-4-methylamphetamine  
DRD Dopamine receptors  
DRD1 Dopamine receptor 1 
DRD2 Dopamine receptor 2 
DRD3 Dopamine receptor 3 
DRD4 Dopamine receptor 4 
DRD5 Dopamine receptor 5 
GPCRs G-protein coupled receptors  
IP3 Nositol-1,4,5-triphosphate  
LSD Lysergic acid diethylamide  
NCF2 Neutrophil cytosol factor 2 
NMDA N-methyl-D-aspartate receptor 
NMDA 3A  N-methyl-D-aspartate receptor 3A  
OPR Opioid receptors  
OPRM Muopioid receptors  
OPRK Kappa opioid receptor  
PIP2 Hydrolyzes phosphatidylinositol  
PKC Protein kinase C 
PLA2 Phospholipase A2  
PLC PI-specific phospholipase C  
RAC Ras-related C3 botulinum toxin substrates 
RAC1 Ras-related C3 botulinum toxin substrate 1 
SAR Structur-activity relationship  
SPRE Sepiapterin reductase 
SSRIs Serotonin reuptake inhibitors  
SUIS Surase-isomaltase  
TCAs Tricyclic antidepressant  
SC6A3 Sodium-dependent dopamine transporter 
SC6A4 Sodium-dependent serotonin transporter 
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ACE Angiotensin-converting enzyme 
NEP Neprilysin 
AA2AR Adenosine receptor A2a 
OPRD Delta opioid receptors  
COMT Catechol O-methyltransferase 
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